News
Fresenius doubles down on biosimilars with big WuXi alliance
Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
News
Aspen, Bambusa close IPOs as Corxel takes SPAC route
Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
News
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
News
AZ seeking $1.5bn in annual savings by end-2029
AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
R&D
Navigating geopolitical risks: Practical and legal mitigatio...
Geopolitical risk is now front of mind for many pharmaceutical leaders.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
